Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Laboratory and clinical parameters of the patients before IVIG therapy

From: Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

Patient Disease
(ILAR Patient criteria)
Disease
duration*
Joint erosion Treatment IgG
antibodies
IgM
antibodies
B19 DNA Anti-PL IgG
      VP1/VP2 NS1 VP1/VP2 NS1 Serum SF Anti-CL Anti-PS Anti-β2GPI
1 RF-positive polyarthritis 23 + NSAID ++ - ++ - 103 102 - - ++
     MTX          
     TCHA          
     Prednisolone (iv/oral)          
2 Psoriatic arthritis 96 + NSAID ++ + + - 4 × 103 3 × 102 - - +
     MTX          
     TCHA          
3 Psoriatic arthritis 48 - NSAID ++ + - - 2 × 103 6 × 103 - - -
     MTX          
     TCHA          
     Prednisone          
4 Reactive arthritis 125 - NSAID ++ - - - 6 × 102 103 - - ++
     Choroquine          
     Prednisone          
     Sulphasalazine          
  1. *Months before IVIG therapy. Genome equivalents per ml of sample. Anti-β2GPI, anti-β2-glycoprotein I; anti-CL, anti-cardiolipin; anti-PL IgG; antiphospholipid antibodies; anti-PS, anti-phosphatidylserine; ILAR, International League of Associations for Rheumatology; iv, intravenous; IVIG, high-dose intravenous immunoglobulin; MTX, methotrexate; NS1, nonstructural protein 1; NSAID, nonsteroidal anti-inflammatory drugs; RF, rheumatoid factor; SF, synovial fluid; TCHA, intra-articularly injected crystalline glucosteroids; VP1, viral protein 1; VP2, viral protein 2.